1. VakilN, van ZantenSV, KahrilasP, et al.The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‐based consensus. Am J Gastroenterol2006;101:1900. CrossRef

2. DentJ, El‐SeragHB, WallanderMA, et al.Epidemiology of gastro‐oesophageal reflux disease: a systematic review. Gut2005;54:710. CrossRef

3. ZagariRM, FuccioL, WallanderMA, et al.Gastro‐oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano‐Monghidoro study. Gut2008;57:1354. CrossRef

4. CamilleriM, DuboisD, CoulieB, et al.Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol2005;3:543. CrossRef

5. ShiG, Bruley des VarannesS, ScarpignatoC, et al.Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut1995;37:457. CrossRef

6. GalmicheJP, ClouseRE, BalintA, et al.Functional esophageal disorders. Gastroenterology2006;130:1459. CrossRef

7. DentJ, VakilN, JonesR, et al.Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut2010;59:714. CrossRef

8. BytzerP, JonesR, VakilN, et al.Limited ability of the proton‐pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol2012;10:1360. CrossRef

9. MenonS, PrewS, ParkesG, et al.Do differences in female sex hormone levels contribute to gastro‐oesophageal reflux disease?Eur J Gastroenterol Hepatol2013;25:772 CrossRef

10. WienbeckM, BarnertJ. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl1989;156:7. CrossRef

11. El‐SeragH, HillC, JonesR. Systematic review: the epidemiology of gastro‐oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther2009;29:470. CrossRef

12. MalfertheinerSF, MalfertheinerMV, KropfS, et al.A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol2012;12:131. CrossRef

13. ReyE, Rodriguez‐ArtalejoF, HerraizMA, et al.Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol2007;102:2395. CrossRef

14. RichterJE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am2003;32:235. CrossRef

15. LiYM, DuJ, ZhangH, et al.Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. J Gastroenterol Hepatol2008;23:283. CrossRef

16. MaXQ, CaoY, WangR, et al.Prevalence of, and factors associated with, gastroesophageal reflux disease: a population‐based study in Shanghai, China. Dis Esophagus2009;22:317. CrossRef

17. WangR, YanX, MaXQ, et al.Burden of gastroesophageal reflux disease in Shanghai, China. Dig Liver Dis2009;41:110. CrossRef

18. SharmaP, WaniS, RomeroY, et al.Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol2008;103:2669. CrossRef

19. CheungTK, WongBC, LamSK. Gastro‐oesophageal reflux disease in Asia : birth of a ‘new’ disease?Drugs2008;68:399. CrossRef

20. El‐SeragHB, SonnenbergA. Opposing time trends of peptic ulcer and reflux disease. Gut1998;43:327. CrossRef

21. Centers for Disease Control and Prevention. Prevalence of overweight, obesity and extreme obesity among adults: United States, trends 1960–62 through 2005–06. 2009. http://www.cdc.gov/nchs/data/hestat/overweight/overweight_adult.htm Accessed 12 July 2010.

22. HansenJM, Wildner‐ChristensenM, Schaffalitzky de MuckadellOB. Gastroesophageal reflux symptoms in a Danish population: a prospective follow‐up analysis of symptoms, quality of life, and health‐care use. Am J Gastroenterol2009;104:2394. CrossRef

23. RuigomezA, Garcia RodriguezLA, WallanderMA, et al.Natural history of gastro‐oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther2004;20:751. CrossRef

24. Nasseri‐MoghaddamS, MofidA, GhotbiMH, et al.Epidemiological study of gastro‐oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther2008;28:144. CrossRef

25. FassR, QuanSF, O'ConnorGT, et al.Predictors of heartburn during sleep in a large prospective cohort study. Chest2005;127:1658. CrossRef

26. DoreMP, MaragkoudakisE, FraleyK, et al.Diet, lifestyle and gender in gastro‐esophageal reflux disease. Dig Dis Sci2008;53:2027. CrossRef

27. NoconM, LabenzJ, JaspersenD, et al.Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol2007;22:1728. CrossRef

28. KamatP, WenS, MorrisJ, et al.Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta‐analysis. Ann Thorac Surg2009;87:655. CrossRef

29. RaghunathA, HunginAP, WooffD, et al.Prevalence of Helicobacter pylori in patients with gastro‐oesophageal reflux disease: systematic review. BMJ2003;326:737. CrossRef

30. RaghunathAS, HunginAP, WooffD, et al.Systematic review: the effect of Helicobacter pylori and its eradication on gastro‐oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther2004;20:733. CrossRef

31. SouzaRC, LimaJH. Helicobacter pylori and gastroesophageal reflux disease: a review of this intriguing relationship. Dis Esophagus2009;22:256. CrossRef

32. el‐OmarEM, PenmanID, ArdillJE, et al.Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology1995;109:681. CrossRef

33. RajendraS, AckroydR, RobertsonIK, et al.Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter2007;12:177. CrossRef

34. MiyamotoM, HarumaK, KuwabaraM, et al.High incidence of newly‐developed gastroesophageal reflux disease in the Japanese community: a 6‐year follow‐up study. J Gastroenterol Hepatol2008;23:393. CrossRef

35. LagergrenJ, BergstromR, AdamiHO, et al.Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med2000;133:165. CrossRef

36. MostaghniA, MehrabaniD, KhademolhosseiniF, et al.Prevalence and risk factors of gastroesophageal reflux disease in Qashqai migrating nomads, southern Iran. World J Gastroenterol2009;15:961. CrossRef

37. GunasekaranTS, DahlbergM, RameshP, et al.Prevalence and associated features of gastroesophageal reflux symptoms in a Caucasian‐predominant adolescent school population. Dig Dis Sci2008;53:2373. CrossRef

38. Ismail‐BeigiF, HortonPF, PopeCE2nd.Histological consequences of gastroesophageal reflux in man. Gastroenterology1970;58:163.

39. RonkainenJ, AroP, StorskrubbT, et al.High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol2005;40:275. CrossRef

40. IsolauriJ, LuostarinenM, IsolauriE, et al.Natural course of gastroesophageal reflux disease: 17–22 year follow‐up of 60 patients. Am J Gastroenterol1997;92:37.

41. CorderAP, JonesRH, SadlerGH, et al.Heartburn, oesophagitis and Barrett's oesophagus in self‐medicating patients in general practice. Br J Clin Pract1996;50:245.

42. MastracciL, SpaggiariP, GrilloF, et al.Microscopic esophagitis in gastro‐esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. Virchows Arch2009;454:31. CrossRef

43. DentJ. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol2007;5:4. CrossRef

44. ZentilinP, SavarinoV, MastracciL, et al.Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol2005;100:2299. CrossRef

45. SavarinoE, ZentilinP, MastracciL, et al.Microscopic esophagitis distinguishes patients with non‐erosive reflux disease from those with functional heartburn. J Gastroenterol2012;48:473 CrossRef

46. LiacourasCA, FurutaGT, HiranoI, et al.Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol2011;128:3, e6, quiz 2122. CrossRef

47. Molina‐InfanteJ, Ferrando‐LamanaL, RipollC, et al.Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol2011;9:110. CrossRef

48. SharmaP, WaniS, BansalA, et al.A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology2007;133:454, quiz 674. CrossRef

49. ChuCL, ZhenYB, LvGP, et al.Microalterations of esophagus in patients with non‐erosive reflux disease: in‐vivo diagnosis by confocal laser endomicroscopy and its relationship with gastroesophageal reflux. Am J Gastroenterol2012;107:864. CrossRef

50. MittalRK, BalabanDH. The esophagogastric junction. N Engl J Med1997;336:924. CrossRef

51. KwiatekMA, PandolfinoJE, KahrilasPJ. 3D‐high resolution manometry of the esophagogastric junction. Neurogastroenterol Motil2011;23:e461. CrossRef

52. NicodemeF, LinZ, PandolfinoJE, et al.Esophagogastric Junction pressure morphology: comparison between a station pull‐through and real‐time 3D‐HRM representation. Neurogastroenterol Motil2013;25:e591 CrossRef

53. BrasseurJG, UlerichR, DaiQ, et al.Pharmacological dissection of the human gastro‐oesophageal segment into three sphincteric components. J Physiol2007;580:961. CrossRef

54. AltschulerSM, BoyleJT, NixonTE, et al.Simultaneous reflex inhibition of lower esophageal sphincter and crural diaphragm in cats. Am J Physiol1985;249:G586.

55. MittalRK, FisherM, McCallumRW, et al.Human lower esophageal sphincter pressure response to increased intra‐abdominal pressure. Am J Physiol1990;258:G624.

56. KleinWA, ParkmanHP, DempseyDT, et al.Sphincterlike thoracoabdominal high pressure zone after esophagogastrectomy. Gastroenterology1993;105:1362. CrossRef

57. JonesMP, SloanSS, RabineJC, et al.Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol2001;96:1711. CrossRef

58. ClouseRE, StaianoA, AlrakawiA, et al.Application of topographical methods to clinical esophageal manometry. Am J Gastroenterol2000;95:2720. CrossRef

59. PandolfinoJE, KimH, GhoshSK, et al.High‐resolution manometry of the EGJ: an analysis of crural diaphragm function in GERD. Am J Gastroenterol2007;102:1056. CrossRef

60. BredenoordAJ, WeustenBL, TimmerR, et al.Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenterology2006;130:334. CrossRef

61. PandolfinoJE, ShiG, CurryJ, et al.Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol Gastrointest Liver Physiol2002;282:G1052. CrossRef

62. PandolfinoJE, ShiG, TrueworthyB, et al.Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology2003;125:1018. CrossRef

63. KwiatekMA, PandolfinoJE, HiranoI, et al.Esophagogastric junction distensibility assessed with an endoscopic functional luminal imaging probe (EndoFLIP). Gastrointest Endosc2010;72:272. CrossRef

64. SloanS, KahrilasPJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology1991;100:596.

65. MittalRK, LangeRC, McCallumRW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology1987;92:130.

66. KahrilasPJ, McCollK, FoxM, et al.The acid pocket: a target for treatment in reflux disease?Am J Gastroenterol2013;108:1058 CrossRef

67. FletcherJ, WirzA, YoungJ, et al.Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology2001;121:775. CrossRef

68. BeaumontH, BenninkRJ, de JongJ, et al.The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut2010;59:441. CrossRef

69. KwiatekMA, KahrilasPJ. Physiology of the LES. Dis Esophagus2012;25:286. CrossRef

70. BiancaniP, HillemeierC, BitarKN, et al.Contraction mediated by Ca2+ influx in esophageal muscle and by Ca2+ release in the LES. Am J Physiol1987;253:G760.

71. GoyalRK, RattanS. Genesis of basal sphincter pressure: effect of tetrodotoxin on lower esophageal sphincter pressure in opossum in vivo. Gastroenterology1976;71:62.

72. DoddsWJ, DentJ, HoganWJ, et al.Effect of atropine on esophageal motor function in humans. Am J Physiol1981;240:G290.

73. SloanS, RademakerAW, KahrilasPJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both?Ann Intern Med1992;117:977. CrossRef

74. HollowayRH, PenaginiR, IrelandAC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol1995;268:G128.

75. KahrilasPJ, DoddsWJ, DentJ, et al.Upper esophageal sphincter function during belching. Gastroenterology1986;91:133.

76. WymanJB, DentJ, HeddleR, et al.Control of belching by the lower oesophageal sphincter. Gut1990;31:639. CrossRef

77. ZhangQ, LehmannA, RigdaR, et al.Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro‐oesophageal reflux disease. Gut2002;50:19. CrossRef

78. SifrimD, HollowayR, SilnyJ, et al.Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol2001;96:647. CrossRef

79. TrudgillNJ, RileySA. Transient lower esophageal sphincter relaxations are no more frequent in patients with gastroesophageal reflux disease than in asymptomatic volunteers. Am J Gastroenterol2001;96:2569. CrossRef

80. BredenoordAJ, FoxM, KahrilasPJ, et al.Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil2012;24(Suppl 1):57. CrossRef

81. RohofWO, BoeckxstaensGE, HirschDP. High‐resolution esophageal pressure topography is superior to conventional sleeve manometry for the detection of transient lower esophageal sphincter relaxations associated with a reflux event. Neurogastroenterol Motil2011;23:427, e173. CrossRef

82. RomanS, ZerbibF, BelhocineK, et al.High resolution manometry to detect transient lower oesophageal sphincter relaxations: diagnostic accuracy compared with perfused‐sleeve manometry, and the definition of new detection criteria. Aliment Pharmacol Ther2011;34:384. CrossRef

83. BredenoordAJ, WeustenBL, TimmerR, et al.Sleeve sensor versus high‐resolution manometry for the detection of transient lower esophageal sphincter relaxations. Am J Physiol Gastrointest Liver Physiol2005;288:G1190. CrossRef

84. KwiatekMA, PostJ, PandolfinoJE, et al.Transient lower oesophageal sphincter relaxation in achalasia: everything but LOS relaxation. Neurogastroenterol Motil2009;21:1294. CrossRef

85. PandolfinoJE, GhoshSK, ZhangQ, et al.Upper sphincter function during transient lower oesophageal sphincter relaxation (tLOSR); it is mainly about microburps. Neurogastroenterol Motil2007;19:203. CrossRef

86. BabaeiA, BhargavaV, MittalRK. Upper esophageal sphincter during transient lower esophageal sphincter relaxation: effects of reflux content and posture. Am J Physiol Gastrointest Liver Physiol2010;298:G601. CrossRef

87. PandolfinoJE, ZhangQG, GhoshSK, et al.Transient lower esophageal sphincter relaxations and reflux: mechanistic analysis using concurrent fluoroscopy and high‐resolution manometry. Gastroenterology2006;131:1725. CrossRef

88. MittalRK, KarstensA, LeslieE, et al.Ambulatory high‐resolution manometry, lower esophageal sphincter lift and transient lower esophageal sphincter relaxation. Neurogastroenterol Motil2012;24:40, e2. CrossRef

89. LangIM, MeddaBK, ShakerR. Digestive and respiratory tract motor responses associated with eructation. Am J Physiol Gastrointest Liver Physiol2013;304:G1044. CrossRef

90. PenaginiR, BraviI. The role of delayed gastric emptying and impaired oesophageal body motility. Best Pract Res Clin Gastroenterol2010;24:831. CrossRef

91. XiaoYL, PengS, TaoJ, et al.Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol2010;105:2626. CrossRef

92. HelmJF, DoddsWJ, PelcLR, et al.Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med1984;310:284. CrossRef

93. BredenoordAJ, WeustenBL, TimmerR, et al.Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. Am J Gastroenterol2006;101:2470. CrossRef

94. LinS, KeM, XuJ, et al.Impaired esophageal emptying in reflux disease. Am J Gastroenterol1994;89:1003.

95. KahrilasPJ, DoddsWJ, HoganWJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology1988;94:73.

96. KahrilasPJ, DoddsWJ, HoganWJ, et al.Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology1986;91:897.

97. LeiteLP, JohnstonBT, BarrettJ, et al.Ineffective esophageal motility (IEM): the primary finding in patients with nonspecific esophageal motility disorder. Dig Dis Sci1997;42:1859. CrossRef

98. SimrenM, SilnyJ, HollowayR, et al.Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut2003;52:784. CrossRef

99. SinghS, BradleyLA, RichterJE. Determinants of oesophageal ‘alkaline’ pH environment in controls and patients with gastro‐oesophageal reflux disease. Gut1993;34:309. CrossRef

100. SchneyerLH, PigmanW, HanahanL, et al.Rate of flow of human parotid, sublingual, and submaxillary secretions during sleep. J Dent Res1956;35:109. CrossRef

101. KorstenMA, RosmanAS, FishbeinS, et al.Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med1991;90:701. CrossRef

102. KahrilasPJ, GuptaRR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med1989;114:431.

103. SarosiekJ, FengT, McCallumRW. The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci1991;302:359. CrossRef

104. KongaraK, VarilekG, SofferEE. Salivary growth factors and cytokines are not deficient in patients with gastroesophageal reflux disease or Barrett's esophagus. Dig Dis Sci2001;46:606. CrossRef

105. RourkRM, NamiotZ, EdmundsMC, et al.Diminished luminal release of esophageal epidermal growth factor in patients with reflux esophagitis. Am J Gastroenterol1994;89:1177.

106. OrlandoRC. Review article: oesophageal mucosal resistance. Aliment Pharmacol Ther1998;12:191. CrossRef

107. HirschowitzBI, SimmonsJL, JohnsonLF, et al.Risk factors for esophagitis in extreme acid hypersecretors with and without Zollinger‐Ellison syndrome. Clin Gastroenterol Hepatol2004;2:220. CrossRef

108. OhDS, HagenJA, FeinM, et al.The impact of reflux composition on mucosal injury and esophageal function. J Gastrointest Surg2006;10:787, discussion 796. CrossRef

109. SaloJ, KivilaaksoE. Role of luminal H+ in the pathogenesis of experimental esophagitis. Surgery1982;92:61.

110. SaloJA, KivilaaksoE. Role of bile salts and trypsin in the pathogenesis of experimental alkaline esophagitis. Surgery1983;93:525.

111. SteinHJ, KauerWK, FeussnerH, et al.Bile acids as components of the duodenogastric refluxate: detection, relationship to bilirubin, mechanism of injury, and clinical relevance. Hepatogastroenterology1999;46:66.

112. VaeziMF, RichterJE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology1996;111:1192. CrossRef

113. HirschowitzBI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology1991;101:1149.

114. ChourasiaD, AchyutBR, TripathiS, et al.Genotypic and functional roles of IL‐1B and IL‐1RN on the risk of gastroesophageal reflux disease: the presence of IL‐1B‐511*T/IL‐1RN*1 (T1) haplotype may protect against the disease. Am J Gastroenterol2009;104:2704. CrossRef

115. CarlssonR, DentJ, Bolling‐SternevaldE, et al.The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol1998;33:1023. CrossRef

116. BerstadA, HatlebakkJG. The predictive value of symptoms in gastro‐oesophageal reflux disease. Scand J Gastroenterol Suppl1995;211:1. CrossRef

117. KlauserAG, SchindlbeckNE, Muller‐LissnerSA. Symptoms in gastro‐oesophageal reflux disease. Lancet1990;335:205. CrossRef

118. JacobP, KahrilasPJ, VanagunasA. Peristaltic dysfunction associated with nonobstructive dysphagia in reflux disease. Dig Dis Sci1990;35:939. CrossRef

119. TackJ, BlondeauK, BoecxstaensV, et al.Review article: the pathophysiology, differential diagnosis and management of rumination syndrome. Aliment Pharmacol Ther2011;33:782. CrossRef

120. FassR, AchemSR. Noncardiac chest pain: diagnostic evaluation. Dis Esophagus2012;25:89. CrossRef

121. KahrilasPJ, HughesN, HowdenCW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro‐oesophageal reflux disease. Gut2011;60:1473. CrossRef

122. IrwinRS, CorraoWM, PratterMR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis1981;123:413.

123. HardingSM, RichterJE. The role of gastroesophageal reflux in chronic cough and asthma. Chest1997;111:1389. CrossRef

124. IngAJ, NguMC, BreslinAB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med1994;149:160. CrossRef

125. SifrimD, DupontL, BlondeauK, et al.Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut2005;54:449. CrossRef

126. SmithJA, DecalmerS, KelsallA, et al.Acoustic cough‐reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology2010;139:754. CrossRef

127. HavemannBD, HendersonCA, El‐SeragHB. The association between gastro‐oesophageal reflux disease and asthma: a systematic review. Gut2007;56:1654. CrossRef

128. PearsonJP, ParikhS, OrlandoRC, et al.Review article: reflux and its consequences – the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston‐upon‐Hull, UK, 21–23 April 2010. Aliment Pharmacol Ther2011;33(Suppl 1):1.

129. JackCI, CalverleyPM, DonnellyRJ, et al.Simultaneous tracheal and oesophageal pH measurements in asthmatic patients with gastro‐oesophageal reflux. Thorax1995;50:201. CrossRef

130. HardingSM, SchanCA, GuzzoMR, et al.Gastroesophageal reflux‐induced bronchoconstriction. Is microaspiration a factor?Chest1995;108:1220. CrossRef

131. VaeziMF, HicksDM, AbelsonTI, et al.Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol2003;1:333. CrossRef

132. PoelmansJ, FeenstraL, DemedtsI, et al.The yield of upper gastrointestinal endoscopy in patients with suspected reflux‐related chronic ear, nose, and throat symptoms. Am J Gastroenterol2004;99:1419. CrossRef

133. JacobP, KahrilasPJ, HerzonG. Proximal esophageal pH‐metry in patients with ‘reflux laryngitis’. Gastroenterology1991;100:305.

134. KatzPO. Ambulatory esophageal and hypopharyngeal pH monitoring in patients with hoarseness. Am J Gastroenterol1990;85:38.

135. KawamuraO, ShimoyamaY, HosakaH, et al.Increase of weakly acidic gas esophagopharyngeal reflux (EPR) and swallowing‐induced acidic/weakly acidic EPR in patients with chronic cough responding to proton pump inhibitors. Neurogastroenterol Motil2011;23:411, e172. CrossRef

136. AhmedTF, KhandwalaF, AbelsonTI, et al.Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. Am J Gastroenterol2006;101:470. CrossRef

137. PaceF, Bianchi PorroG. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol2004;99:946. CrossRef

138. PaceF, BollaniS, MolteniP, et al.Natural history of gastro‐oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on. Dig Liver Dis2004;36:111. CrossRef

139. MalfertheinerP, NoconM, ViethM, et al.Evolution of gastro‐oesophageal reflux disease over 5 years under routine medical care – the ProGERD study. Aliment Pharmacol Ther2012;35:154. CrossRef

140. PandeyaN, OlsenCM, WhitemanDC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol2013;37:579 CrossRef

141. LagergrenJ, BergstromR, LindgrenA, et al.Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med1999;340:825. CrossRef

142. RuigomezA, Garcia RodriguezLA, WallanderMA, et al.Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol2006;101:2685. CrossRef

143. GudaNM, VakilN. Proton pump inhibitors and the time trends for esophageal dilation. Am J Gastroenterol2004;99:797. CrossRef

144. HruzP, StraumannA, BussmannC, et al.Escalating incidence of eosinophilic esophagitis: a 20‐year prospective, population‐based study in Olten County, Switzerland. J Allergy Clin Immunol2011;128:1349. CrossRef

145. PrasadGA, AlexanderJA, SchleckCD, et al.Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol2009;7:1055. CrossRef

146. BainbridgeET, TempleJG, NicholasSP, et al.Symptomatic gastro‐oesophageal reflux in pregnancy. A comparative study of white Europeans and Asians in Birmingham. Br J Clin Pract1983;37:53.

147. PandolfinoJE, El‐SeragHB, ZhangQ, et al.Obesity: a challenge to esophagogastric junction integrity. Gastroenterology2006;130:639. CrossRef

148. LeeHL, EunCS, LeeOY, et al.Association between GERD‐related erosive esophagitis and obesity. J Clin Gastroenterol2008;42:672. CrossRef

149. El‐SeragH. Role of obesity in GORD‐related disorders. Gut2008;57:281. CrossRef

150. CorleyDA, KuboA, ZhaoW. Abdominal obesity, ethnicity and gastro‐oesophageal reflux symptoms. Gut2007;56:756. CrossRef

151. FisherBL, PennathurA, MutnickJL, et al.Obesity correlates with gastroesophageal reflux. Dig Dis Sci1999;44:2290. CrossRef

152. SuterM, DortaG, GiustiV, et al.Gastro‐esophageal reflux and esophageal motility disorders in morbidly obese patients. Obes Surg2004;14:959. CrossRef

153. IovinoP, AngrisaniL, TremolaterraF, et al.Abnormal esophageal acid exposure is common in morbidly obese patients and improves after a successful Lap‐band system implantation. Surg Endosc2002;16:1631. CrossRef

154. SabateJM, JouetP, MerroucheM, et al.Gastroesophageal reflux in patients with morbid obesity: a role of obstructive sleep apnea syndrome?Obes Surg2008;18:1479. CrossRef

155. WuJC, MuiLM, CheungCM, et al.Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology2007;132:883. CrossRef

156. HongD, KhajancheeYS, PereiraN, et al.Manometric abnormalities and gastroesophageal reflux disease in the morbidly obese. Obes Surg2004;14:744. CrossRef

157. JaffinBW, KnoepflmacherP, GreensteinR. High prevalence of asymptomatic esophageal motility disorders among morbidly obese patients. Obes Surg1999;9:390. CrossRef

158. KoppmanJS, PoggiL, SzomsteinS, et al.Esophageal motility disorders in the morbidly obese population. Surg Endosc2007;21:761. CrossRef

159. QuirogaE, Cuenca‐AbenteF, FlumD, et al.Impaired esophageal function in morbidly obese patients with gastroesophageal reflux disease: evaluation with multichannel intraluminal impedance. Surg Endosc2006;20:739. CrossRef

160. RomanS, HotA, FabienN, et al.Esophageal dysmotility associated with systemic sclerosis: a high‐resolution manometry study. Dis Esophagus2011;24:299. CrossRef

161. MarieI, DominiqueS, LevesqueH, et al.Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum2001;45:346. CrossRef

162. MarieI, DucrotteP, DenisP, et al.Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther2006;24:1593. CrossRef

163. SavarinoE, BazzicaM, ZentilinP, et al.Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH‐impedance monitoring. Am J Respir Crit Care Med2009;179:408. CrossRef

164. BonattiH, AchemSR, HinderRA. Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment. J Gastrointest Surg2008;12:373. CrossRef

165. HorikawaA, Ishii‐NozawaR, OhguroM, et al.Prevalence of GORD (gastro‐oesophageal reflux disease) in Type 2 diabetes and a comparison of clinical profiles between diabetic patients with and without GORD. Diabet Med2009;26:228. CrossRef

166. EslickGD, TalleyNJ. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life‐a population‐based study. J Clin Gastroenterol2009;43:111. CrossRef

167. WangX, PitchumoniCS, ChandraranaK, et al.Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol2008;14:709. CrossRef

168. MillerLS, VinayekR, FruchtH, et al.Reflux esophagitis in patients with Zollinger‐Ellison syndrome. Gastroenterology1990;98:341. CrossRef

169. JanssonC, NordenstedtH, WallanderMA, et al.Severe symptoms of gastro‐oesophageal reflux disease are associated with cardiovascular disease and other gastrointestinal symptoms, but not diabetes: a population‐based study. Aliment Pharmacol Ther2008;27:58. CrossRef

170. BasseriB, ConklinJL, PimentelM, et al.Esophageal motor dysfunction and gastroesophageal reflux are prevalent in lung transplant candidates. Ann Thorac Surg2010;90:1630. CrossRef

171. DavisCS, ShankaranV, KovacsEJ, et al.Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment. Surgery2010;148:737, discussion 744. CrossRef

172. MendezBM, DavisCS, WeberC, et al.Gastroesophageal reflux disease in lung transplant patients with cystic fibrosis. Am J Surg2012;204:e21. CrossRef

173. ShahN, ForceSD, MitchellPO, et al.Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. Transplant Proc2010;42:2702. CrossRef

174. ParadaMT, AlbaA, SepulvedaC. Bronchiolitis obliterans syndrome development in lung transplantation patients. Transplant Proc2010;42:331. CrossRef

175. RichterJE. Severe reflux esophagitis. Gastrointest Endosc Clin N Am1994;4:677.

176. RichterJE, CastellDO. Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy. Ann Intern Med1982;97:93. CrossRef

177. LundellLR, DentJ, BennettJR, et al.Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut1999;45:172. CrossRef

178. PandolfinoJE, VakilNB, KahrilasPJ. Comparison of inter‐ and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc2002;56:639. CrossRef

179. BytzerP, HavelundT, HansenJM. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol1993;28:119. CrossRef

180. PandolfinoJE, VelaMF. Esophageal‐reflux monitoring. Gastrointest Endosc2009;69:917e1. CrossRef

181. JohnsonLF, DemeesterTR. Twenty‐four‐hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol1974;62:325.

182. JohnsonLF, DeMeesterTR. Development of the 24‐hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol1986;8(Suppl 1):52. CrossRef

183. WienerGJ, RichterJE, CopperJB, et al.The symptom index: a clinically important parameter of ambulatory 24‐hour esophageal pH monitoring. Am J Gastroenterol1988;83:358.

184. BreumelhofR, SmoutAJ. The symptom sensitivity index: a valuable additional parameter in 24‐hour esophageal pH recording. Am J Gastroenterol1991;86:160.

185. WeustenBL, RoelofsJM, AkkermansLM, et al.The symptom‐association probability: an improved method for symptom analysis of 24‐hour esophageal pH data. Gastroenterology1994;107:1741.

186. PandolfinoJE, RichterJE, OursT, et al.Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol2003;98:740. CrossRef

187. SweisR, FoxM, AnggiansahA, et al.Prolonged, wireless pH‐studies have a high diagnostic yield in patients with reflux symptoms and negative 24‐h catheter‐based pH‐studies. Neurogastroenterol Motil2011;23:419 CrossRef

188. VelaMF, Camacho‐LobatoL, SrinivasanR, et al.Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology2001;120:1599. CrossRef

189. ZerbibF, RomanS, Bruley Des VarannesS, et al.Normal values of pharyngeal and esophageal 24‐hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol2013;11:366. CrossRef

190. MainieI, TutuianR, ShayS, et al.Acid and non‐acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance‐pH monitoring. Gut2006;55:1398. CrossRef

191. SavarinoE, PohlD, ZentilinP, et al.Functional heartburn has more in common with functional dyspepsia than with non‐erosive reflux disease. Gut2009;58:1185. CrossRef

192. PritchettJM, AslamM, SlaughterJC, et al.Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol2009;7:743. CrossRef

193. GarreanCP, ZhangQ, GonsalvesN, et al.Acid reflux detection and symptom‐reflux association using 4‐day wireless pH recording combining 48‐hour periods off and on PPI therapy. Am J Gastroenterol2008;103:1631. CrossRef

194. PandolfinoJE, KahrilasPJ. AGA technical review on the clinical use of esophageal manometry. Gastroenterology2005;128:209. CrossRef

195. PorterRF, KumarN, DrapekinJE, et al.Fragmented esophageal smooth muscle contraction segments on high resolution manometry: a marker of esophageal hypomotility. Neurogastroenterol Motil2012;24:763, e353. CrossRef

196. DaumC, SweisR, KaufmanE, et al.Failure to respond to physiologic challenge characterizes esophageal motility in erosive gastro‐esophageal reflux disease. Neurogastroenterol Motil2011;23:517‐e200. CrossRef

197. VaeziMF, LacameraRG, RichterJE. Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring system. Am J Physiol1994;267:G1050.

198. KahrilasPJ, ShaheenNJ, VaeziMF, et al.American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology2008;135:1383, 1391 e1. CrossRef

199. HampelH, AbrahamNS, El‐SeragHB. Meta‐analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med2005;143:199. CrossRef

200. KjellinA, RamelS, RossnerS, et al.Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol1996;31:1047. CrossRef

201. Fraser‐MoodieCA, NortonB, GornallC, et al.Weight loss has an independent beneficial effect on symptoms of gastro‐oesophageal reflux in patients who are overweight. Scand J Gastroenterol1999;34:337. CrossRef

202. JacobsonBC, SomersSC, FuchsCS, et al.Body‐mass index and symptoms of gastroesophageal reflux in women. N Engl J Med2006;354:2340. CrossRef

203. MandelKG, DaggyBP, BrodieDA, et al.Review article: alginate‐raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther2000;14:669. CrossRef

204. KwiatekMA, RomanS, FareeduddinA, et al.An alginate‐antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther2011;34:59 CrossRef

205. SweisR, KaufmanE, AnggiansahA, et al.Post‐prandial reflux suppression by a raft‐forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH‐impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double‐blind study in reflux patients. Aliment Pharmacol Ther2013;37:1093 CrossRef

206. VakilNB, TraxlerB, LevineD. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol2004;2:665. CrossRef

207. KahrilasPJ, HowdenCW, HughesN. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol2011;106:1419 CrossRef

208. ChangAB, LassersonTJ, GaffneyJ, et al.Gastro‐oesophageal reflux treatment for prolonged non‐specific cough in children and adults. Cochrane Database Syst Rev2011;(1):CD004823.

209. HetzelDJ, DentJ, ReedWD, et al.Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology1988;95:903.

210. ShinJM, SachsG. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep2008;10:528. CrossRef

211. LindT, RydbergL, KylebackA, et al.Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2000;14:861. CrossRef

212. TytgatGN, McCollK, TackJ, et al.New algorithm for the treatment of gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2008;27:249. CrossRef

213. FassR, SontagSJ, TraxlerB, et al.Treatment of patients with persistent heartburn symptoms: a double‐blind, randomized trial. Clin Gastroenterol Hepatol2006;4:50. CrossRef

214. BeckerV, BajboujM, WallerK, et al.Clinical trial: persistent gastro‐oesophageal reflux symptoms despite standard therapy with proton pump inhibitors – a follow‐up study of intraluminal‐impedance guided therapy. Aliment Pharmacol Ther2007;26:1355. CrossRef

215. ZvyagaT, ChangSY, ChenC, et al.Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos2012;40:1698. CrossRef

216. AdachiK, KatsubeT, KawamuraA, et al.CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther2000;14:1259. CrossRef

217. SagarM, TybringG, DahlML, et al.Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology2000;119:670. CrossRef

218. LaineL, HennekensC. Proton pump inhibitor and clopidogrel interaction: fact or fiction?Am J Gastroenterol2010;105:34. CrossRef

219. KatzPO, GersonLB, VelaMF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol2013;108:308, quiz 329. CrossRef

220. NgamruengphongS, LeontiadisGI, RadhiS, et al.Proton pump inhibitors and risk of fracture: a systematic review and meta‐analysis of observational studies. Am J Gastroenterol2011;106:1209, quiz 1219. CrossRef

221. TargownikLE, LeslieWD, DavisonKS, et al.The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population‐based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol2012;107:1361. CrossRef

222. YangYX, MetzDC. Safety of proton pump inhibitor exposure. Gastroenterology2010;139:1115. CrossRef

223. RobertsonDJ, LarssonH, FriisS, et al.Proton pump inhibitor use and risk of colorectal cancer: a population‐based, case‐control study. Gastroenterology2007;133:755. CrossRef

224. van SoestEM, van RossumLG, DielemanJP, et al.Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol2008;103:966. CrossRef

225. SinghM, DhindsaG, FriedlandS, et al.Long‐term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas. Aliment Pharmacol Ther2007;26:1051. CrossRef

226. LoWK, ChanWW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta‐analysis. Clin Gastroenterol Hepatol2013;11:483. CrossRef

227. CundyT, MackayJ. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol2011;27:180. CrossRef

228. KhanM, SantanaJ, DonnellanC, et al.Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev2007;(2):CD003244.

229. van PinxterenB, SigtermanKE, BonisP, et al.Short‐term treatment with proton pump inhibitors, H2‐receptor antagonists and prokinetics for gastro‐oesophageal reflux disease‐like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev2010;(11):CD002095.

230. HatlebakkJG, KatzPO, KuoB, et al.Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther1998;12:1235. CrossRef

231. FacklerWK, OursTM, VaeziMF, et al.Long‐term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology2002;122:625. CrossRef

232. GersonLB, HuffFJ, HilaA, et al.Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol2010;105:1266. CrossRef

233. BoeckxstaensGE, BeaumontH, MertensV, et al.Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology2010;139:409. CrossRef

234. CiccaglioneAF, MarzioL. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro‐oesophageal reflux disease. Gut2003;52:464. CrossRef

235. BoeckxstaensGE, BeaumontH, HatlebakkJG, et al.A novel reflux inhibitor lesogaberan (AZD3355) as add‐on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo‐controlled trial. Gut2011;60:1182 CrossRef

236. ZerbibF, Bruley des VarannesS, RomanS, et al.Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2011;33:911. CrossRef

237. DurazoFA, ValenzuelaJE. Effect of single and repeated doses of metoclopramide on the mechanisms of gastroesophageal reflux. Am J Gastroenterol1993;88:1657.

238. YangM, LiZS, ChenDF, et al.Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. Clin J Pain2010;26:326. CrossRef

239. PrakashC, ClouseRE. Long‐term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci1999;44:2373. CrossRef

240. ClouseRE, LustmanPJ, EckertTC, et al.Low‐dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double‐blind, placebo‐controlled trial. Gastroenterology1987;92:1027.

241. BroekaertD, FischlerB, SifrimD, et al.Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled study. Aliment Pharmacol Ther2006;23:365. CrossRef

242. ViazisN, KeyoglouA, KanellopoulosAK, et al.Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double‐blind, placebo‐controlled study. Am J Gastroenterol2012;107:1662. CrossRef

243. DickmanR, SchiffE, HollandA, et al.Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther2007;26:1333. CrossRef

244. NojkovB, RubensteinJH, AdlisSA, et al.The influence of co‐morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther2008;27:473. CrossRef

245. KieblesJL, KwiatekMA, PandolfinoJE, et al.Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus2010;23:545. CrossRef

246. RydbergL, RuthM, LundellL. Mechanism of action of antireflux procedures. Br J Surg1999;86:405. CrossRef

247. JohnssonF, HollowayRH, IrelandAC, et al.Effect of fundoplication on transient lower oesophageal sphincter relaxation and gas reflux. Br J Surg1997;84:686. CrossRef

248. LundellL, AttwoodS, EllC, et al.Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro‐oesophageal reflux disease: a 3‐year interim analysis of the LOTUS trial. Gut2008;57:1207. CrossRef

249. GalmicheJP, HatlebakkJ, AttwoodS, et al.Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD. The LOTUS randomized clinical trial. JAMA2011;305:1969. CrossRef

250. VakilN, ShawM, KirbyR. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med2003;114:1. CrossRef

251. HunterJG, SmithCD, BranumGD, et al.Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg1999;230:595, discussion 604. CrossRef

252. BellRC, CadiereGB. Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. Surg Endosc2011;25:2387 CrossRef

253. FrazzoniM, ConigliaroR, MantaR, et al.Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. Aliment Pharmacol Ther2011;34:67 CrossRef

254. TestoniPA, CorsettiM, Di PietroS, et al.Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph‐impedance refluxes of GERD patients. World J Surg2010;34:750. CrossRef

255. BonavinaL, DeMeesterT, FockensP, et al.Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one‐ and 2‐year results of a feasibility trial. Ann Surg2010;252:857. CrossRef

256. BansalA, KahrilasPJ. Treatment of GERD complications (Barrett's, peptic stricture) and extra‐oesophageal syndromes. Best Pract Res Clin Gastroenterol2010;24:961. CrossRef